MDB Capital Holdings (MDBH) Company Report

MDB Capital Holdings utilized $5.9 million for operating expenses during the first three quarters of Q3 2025 and anticipates a strong fourth quarter where revenue is expected to offset these expenses.
The company expects to finalize the closing of Pollex and price Buda Juice in the near future, which would mark the first time MDBH has completed two company launches in a single quarter.
MDBH aims to scale its operations to 3-5 launches per year, with 4-5 companies currently in late-stage negotiations for the upcoming year, and expresses optimism for a resurgence in the microcap market.
CEO Christopher Marlett believes the company's stock is undervalued, citing significant equity holdings in companies such as Exazyme and Heartbeat, along with other assets like Patentvest and its clearing platform, which are not fully reflected in the current stock price.

Nov 20, 2025, 9:30 PM

MDB Capital Holdings Provides Q3 2025 Update and Strategic Outlook

MDBH

Earnings

New Projects/Investments

Guidance Update

MDB Capital Holdings reported $5.9 million in operating expenses for the first three quarters of 2025 and anticipates a strong fourth quarter where revenue is expected to offset these expenses.
The company is focused on scaling its public venture launch operations to three to five companies per year and holds significant equity positions in key ventures such as Exazyme and Heartbeat, with Heartbeat awaiting FDA approval for its device.
Management views the company's stock as undervalued, noting that the market value of its equity holdings in companies like Exazyme and Heartbeat, plus cash, significantly exceeds its current market capitalization.
MDBH also plans to spin out Patentvest, which it considers an undervalued asset with the potential to become the first public patent law firm in the US.

Nov 20, 2025, 9:30 PM

MDB Capital Holdings Discusses Q3 2025 Performance and Future Strategy

MDBH

Earnings

Guidance Update

New Projects/Investments

MDB Capital Holdings (MDBH) is focused on scaling its public venture operations to three to five launches per year, aiming to transform early-stage companies with billion-dollar-plus potential. The company has a historical record of never failing an IPO and 100% of its IPOs trading at 2x the IPO price at some point post-IPO.
For the first three quarters of FY2025, MDBH incurred approximately $5.9 million in operating expenses and anticipates a good fourth quarter with revenue expected to offset these costs.
MDBH highlights significant, currently undervalued equity holdings in companies like Exazyme and Heartbeat, with Heartbeat nearing FDA approval for its virtual cardiologist product. Additionally, Patentvest investments and the clearing platform are considered undervalued assets not reflected on the balance sheet.
Upcoming launches include Buddha Juice, a profitable category leader in fresh juice, and Pollex Bio, a biotech company with a $40 million post-money valuation and potential for a multi-billion dollar valuation after Phase 1B results in about a year, in which MDBH will own 6 or 7 million shares.

Nov 20, 2025, 9:30 PM

MDB Capital Provides Q3 2025 Update, Highlights Upcoming Offerings and Undervaluation

MDBH

Earnings

Guidance Update

New Projects/Investments

MDB Capital (MDBH) reported a net cash use in operational activities of approximately $5.9 million through the first three quarters of 2025.
The company anticipates closing a $16.8 million private placement for Paulex Bio this week and a $20 million IPO for Buda Juice in December, which are expected to generate positive cash and add to equity holdings.
MDBH believes it is significantly undervalued, with a market capitalization of $34.1 million compared to an estimated value of $78.7 million as of September 30, 2025, and its equity in eXoZymes (EXOZ) alone is 1.7 times its current market cap.
MDB Capital maintains a 100% IPO success rate for companies launched, with every company trading at a 100%+ premium to its IPO price, and aims for 3-5 launches per year to cover its $10 million annual operating expenses.

Nov 20, 2025, 9:30 PM

MDB Capital Holdings Discusses "Public Venture" Model and Future Growth

MDBH

New Projects/Investments

Demand Weakening

Revenue Acceleration/Inflection

MDB Capital Holdings operates a "public venture" model, having launched 17 companies with a 100% IPO sell rate; 30% of these achieved billion-dollar market values and 60% reached $500 million or greater.
The company aims to scale its launches from one company every 18 months to three or four per year, with a current focus on metabolic health and plans to spin out its IP law firm as a public company.
MDBH, a publicly traded LLC, provides investors with priority access to its IPOs and notes that all its launched companies qualify for QSBS 1201 tax benefits.
While the small-cap IPO market has been challenging in the last three years, MDBH expresses optimism for a turnaround.

Oct 21, 2025, 5:30 PM

MDBH Discusses Public Venture Strategy and Growth Initiatives

MDBH

New Projects/Investments

Revenue Acceleration/Inflection

MDBH operates a "public venture" model, focusing on launching highly curated microcap companies, primarily in deep tech, with a track record of 30% of 17 launched companies reaching billion-dollar market values and 60% reaching $500 million or greater.
The firm aims to scale its operations, increasing the launch rate from one company every 18 months to three or four per year.
MDBH's current market capitalization is $35 million, and it provides investors with priority access to its IPOs.
All companies launched by MDBH qualify for QSPS-twelve oh two, offering tax advantages for long-term investors.
MDBH plans to spin out its IP law firm as a public company and is actively developing three pipeline companies in metabolic health, projected to become billion-dollar plus companies.